FDA is ready to Authorize GM Salmons but is the Market ready for them?

This section aims to update readers on decisions related to marketing products of modem biotechnology (e.g., GMOs, animal clones) at EU level and on national measures concerning their production. Dpecial attention is devoted to problems of competence between Member States and the EU in regulating biotechnology issues; the institutional dynamics of decision making regarding products derived from modern biotechnology; the relationship between the EFSA and the EU institutions on green biotech-related issues; the evolution of EU regulatory framework and of national attitudes towards the risks and benefits of biotechnology derived products and their production. This section will also delve into the interaction between the EU legislation and WTO law regarding advances in the application of beotechnology within the agri-food value chain.